Last reviewed · How we verify
Exenatide placebo (saline)
This is a placebo (saline injection) with no active pharmacological mechanism.
This is a placebo (saline injection) with no active pharmacological mechanism. Used for Control arm in clinical trials of exenatide for type 2 diabetes.
At a glance
| Generic name | Exenatide placebo (saline) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Exenatide placebo saline is an inert control formulation used in clinical trials to compare against the active GLP-1 receptor agonist exenatide. It contains no active drug and serves as a comparator to establish the efficacy and safety profile of exenatide in randomized controlled studies.
Approved indications
- Control arm in clinical trials of exenatide for type 2 diabetes
Common side effects
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) (PHASE4)
- A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease (PHASE2)
- GLP-1 and Hyperoxia for Organ Protection in Heart Surgery (NA)
- Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia (NA)
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide placebo (saline) CI brief — competitive landscape report
- Exenatide placebo (saline) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI